This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Patrick M. Moriarty, MD; Thomas J. Whittaker, JD, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the case reports by Papadaki et al¹ in the November 2006 issue of the Archives. Their results in treating patients with lupus retinal vasculitis were similar to our earlier work using low-density lipoprotein apheresis.² Unlike plasmapheresis, low-density lipoprotein apheresis does not remove albumin or immunoglobulins and has little effect on high-density lipoprotein cholesterol levels. In addition to immediately reducing low-density lipoprotein cholesterol levels by 60% to 80%, low-density lipoprotein apheresis lowers plasma levels of vascular markers, reduces blood viscosity, and improves endothelial function.³ We hypothesize that these changes could lead to an increase of microvascular flow, which may be of major significance during the acute lupus crisis. We concur with Papadaki and colleagues that apheresis may be useful as an adjunctive therapy for retinal vasculitis when immunosuppressants alone are ineffective.

AUTHOR INFORMATION
Correspondence: Dr Moriarty, Department of Internal . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Plasmapheresis for Lupus Retinal Vasculitis
Thekla G. Papadaki, Ioannis P. Zacharopoulos, George Papaliodis, Barbara Iaccheri, Tito Fiore, and C. Stephen Foster
Arch Ophthalmol. 2006;124(11):1654-1656.
EXTRACT | FULL TEXT